Future treatment to lessen exacerbations of chronic obstructive pulmonary disease

Proceedings of the American Thoracic Society

Volumn 4, Issue 8, 2007, Pages 659-666

  Leff, Alan R ^a   Muñoz, Nilda M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Annexin 1; Chronic obstructive pulmonary disease; HIV TAT; Neutrophils; Secretory group V phospholipase A2

Indexed keywords

ANNEXIN; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEUKOTRIENE MODIFYING AGENT; PHOSPHOLIPASE A2; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; HUMAN; INFLAMMATION; NEUTROPHIL; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER;

ANNEXIN A1; ANTI-INFLAMMATORY AGENTS; GROUP IV PHOSPHOLIPASES A2; HUMANS; INFLAMMATION; INTEGRINS; NEUTROPHILS; PHOSPHOLIPASES A2; PHOSPHORYLATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RAS PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC;

EID: 37349025747     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200707-103TH     Document Type: Article

References (42)

1. Taraseviciene-Stewart L, Douglas IS, Nana-Sinkam PS, Lee JD, Tuder R, Nicolls MR, Voelkel NF. Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease? Proc Am Thorac Soc 2006;3:687-690.
2. Henson PM, Vandivier RW, Douglas IS. Cell death, remodeling, and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:713-717.
3. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
4. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, Pavord ID, McCormack D, Chaudhuri R, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007;356:1327-1337.
5. Danek CJ, Lombard CM, Dungworth DL, Cox PG, Miller JD, Biggs MJ, Keast TM, Loomas BE, Wizeman WJ, Hogg JC, et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol 2004;97:1946-1953.
6. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Jorgen B. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
7. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224-1238.
8. Henson PM, Vandivier RW, Douglas IS. Cell death, remodeling, and repair in chronic obstructive pulmonary disease? Proc Am Thorac Soc 2006;3:713-717.
9. Di Stefano A, Caramori G, Ricciardolo FL, Capelli A, Adcock IM, Donner CF. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin Exp Allergy 2004;34:1156-1167.
10. Drost EM, MacNee W. Potential role of IL-8, platelet-activating factor and TNF-a in the sequestration of neutrophils in the lung: effects on neutrophil deformability, adhesion receptor expression, and chemotaxis. Eur J Immunol 2002;32:393-403.
11. Leff AR, Hamann KJ, Wegner CD. Inflammation and cell-cell interactions in airway hyperresponsiveness. Am J Physiol Lung Cell Mol Physiol 1991;260:L189-L206.
12. Muñoz NM, Rabe KF, Neeley SP, Herrnreiter A, Zhu X, McAllister K, Mayer D, Magnussen H, Galens S, Leff AR. Eosinophil VLA-4 binding to fibronectin augments bronchial narrowing through 5-lipoxygenase activation. Am J Physiol 1996;270:L587-L594.
13. 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate. Eur Respir J 2004;23:511-517.
14. 4 inhibitor and glucocorticoid in a murine model of allergic asthma. Life Sci 2006;79:2007-2085.
15. 2-integrin-dependent adhesion of human eosinophils. J Immunol 1999;163:3423-3429.
16. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF. Synthetic protein transduction domains: enhanced transduction potential in vitro. Cancer Res 2001;61:474-477.
17. Ma M, Nath A. Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol 1997;71:2495-2499.
18. 2-integrin-mediated adhesion of eosinophils to intercellular adhesion molecule-1 caused by transduction of HIV TAT-dominant negative Ras. J Immunol 2002;169:2670-2676.
19. Myou S, Zhu X, Myo S, Boetticher E, Meliton AY, Liu J, Muñoz NM, Leff AR. Blockade of airway inflammation and hyperresponsiveness by HIV-TAT-dominant negative Ras. J Immunol 2003;171:4379-4384.
20. Myou S, Leff AR, Myo S, Boetticher E, Tong J, Meliton AY, Liu J, Muñoz NM, Zhu X. Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J Exp Med 2003;198:1573-1582.
21. Ford KG, Souberbielle BE, Darling D, Farzaneh F. Protein transduction: an alternative to genetic intervention? Gene Ther 2001;8:1-4.
22. Okkenhaug K, Vanhaesebroeck B. New responsibilities for the PI3K regulatory subunit p85 α. Sci STKE 2001;65:PE1.
23. Nagase T, Ishii S, Katayama H, Fukuchi Y, Ouchi Y, Shimizu T. Airway responsiveness in transgenic mice overexpressing platelet-activating factor receptor: roles of thromboxanes and leukotrienes. Am J Respir Crit Care Med 1997;156:1621-1627.
24. Ishii S, Nagase T, Shindou H, Takizawa H, Ouchi Y, Shimizu T. Platelet-activating factor receptor develops airway hyperresponsiveness independently of airway inflammation in a murine asthma model. J Immunol 2004;172:7095-7102.
25. 2. Nat Immunol 2000;1:42-46.
26. 4 secretion by fluticasone propionate in exogenously activated human eosinophils. Am J Respir Crit Care Med 1999;159:1903-1909.
27. 2-inhibition. Nat Immunol 2001;2:145-149.
28. Zhu X, Lambertino AT, Houghton TJ, McGilvra JD, Xu C, Rawal VH, Leff AR. Structural determinants of blockade of eosinophil activation, adhesion and secretion by synthetic analogs of phomactin. Life Sci 2003;73:3005-3016.
29. Perretti M, Flower RJ. Annexin-1 and the biology of the neutrophil. J Leukoc Biol 2004;76:25-29.
30. 2 activation. Biophys J 2001;80:789-800.
31. 2-independent cysteinyl leukotriene synthesis in human eosinophils. J Biol Chem 2003;278:38813-38820.
32. 4 in eosinophils. J Immunol 2006;177:574-582.
33. 2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem 2002;277:5061-5073.
34. 2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells. Biochem J 2005;387:27-38.
35. 2 in P388D1 macrophages using GFP/RFP constructs. Biochim Biophys Acta 2005;1735:119-129.
36. 2 in human tissues by sandwich enzyme-linked immunosorbent assay. J Immunol Methods 2002;262:41-51.
37. 2s preferentially expressed in type 2 helper T cells. J Biol Chem 2001;276:18321-18326.
38. 2 internalization and degradation. J Biol Chem 2001;276:11126-11134.
39. 2. J Biol Chem 1999;274:11881-11888.
40. 2. Biochim Biophys Acta 2000;1488:48-58.
41. 2). Hybridoma 2000;19:171-176.
42. 2-integrin adhesion of human eosinophils to intercellular adhesion molecule 1 surrogate protein. J Allergy Clin Immunol 2005;115:493-500.